Bill Snyder Archive — Page 29 of 119

November 10, 2022

AstraZeneca VP to discuss COVID-19 collaboration with VUMC Nov. 17

On Thursday, Nov. 17, Mark Esser, PhD, vice president, Early Vaccines and Immune Therapies R&D at AstraZeneca, will discuss his company’s collaboration with Vanderbilt University Medical Center that led to development of the Evusheld antibody combo to prevent COVID-19 in high-risk individuals.

Jacek Hawiger, MD, PhD, third from right, with study team members, from left, Katherine Gibson-Corley, DVM, PhD, Yan Liu, MD, Jozef Zienkiewicz, PhD, Huan Qiao, MD, PhD, and Ruth Ann Veach.
November 10, 2022

Hawiger still blazing a trail in inflammation research

Vanderbilt research describes a new investigational peptide drug that can penetrate immune and nonimmune cells, and block inflammatory signaling in a preclinical model of atopic dermatitis — eczema.

November 10, 2022

Study defines role of steroids in congenital heart disease surgery

Steroids are commonly given to infants during open-heart surgery to reduce inflammation, but whether the drugs significantly improve patient outcomes has not been settled — until now.

November 4, 2022

Study finds Moderna’s COVID-19 vaccine safe and effective for young children

A Vanderbilt study finds that Moderna’s COVID-19 vaccine is safe and effective in children 6 months to 5 years of age.

Pending COVID-19 samples are prepared for testing in the Diagnostic Laboratories at VUMC.
November 3, 2022

Event to spotlight VUMC’s COVID-19 research efforts

The public is invited to listen in as scientists on the forefront of COVID-19 research at Vanderbilt University Medical Center share their personal stories on Wednesday afternoon, Nov. 16, in 214 Light Hall.

October 28, 2022

VUMC mourns loss of noted hypertension expert Elijovich

Fernando Elijovich, MD, professor of Medicine in the Division of Clinical Pharmacology at Vanderbilt University Medical Center, died in Nashville on Oct. 21. He was 77.